Skip to main content
. Author manuscript; available in PMC: 2011 Nov 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2010 Sep 16;249(1):101–106. doi: 10.1016/j.taap.2010.09.003

Table 1.

Pharmacokinetic parameters for DCBN clearance in WT and Cyp2a5-null mice

Mouse strain T1/2
(h)		 Tmax
(h)		 Cmax
(µg/ml)		 AUC0–24h
(µg*h/ml)		 Clearance
(ml/h)
WT 6.6 ± 6.5 2.3 ± 1.6 0.6 ± 0.3 4.1 ± 0.9 170 ± 60
Cyp2a5-null 5.6 ± 3.7 2.2 ± 1.8 0.7 ± 0.3 4.8 ± 1.5 130 ± 30

Two- to three-month old, male, WT B6 and Cyp2a5-null mice were treated intraperitoneally with DCBN (at 25 mg/kg). Tail blood samples were collected from individual mice at various time points after dosing, for determination of plasma concentrations of DCBN, as described in Materials and Methods. Plasma levels of DCBN were used to calculate various pharmacokinetic parameters. Values represent means ± S.D. (n = 4–5 for each strain). There was no significant difference between the two mouse strains for any of the parameters (P>0.05, Student’s t-test)